Concepedia

Author

Chihiro Kondoh

Toranomon HospitalORCID

Also Known As

C Kondoh, C. Kondoh, C.N. Kondoh, CHIHIRO KONDOH, Chihiro Kondoh, Chihiro N Kondoh, Chihiro Nakayama Kondoh

98

Publications

951

Citations

16

H-Index

24

Concepts

All Affiliations

Toranomon HospitalAichi Cancer CenterNational Cancer Center Hospital EastKeio UniversityShizuoka Cancer Center
CK

About

Chihiro Kondoh is an author at Toranomon Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

184

2

Pathology

3

3

39

3

Health Sciences

2

2

63

4

Immunology

2

2

27

5

Hepatology

1

1

31

Chihiro Kondoh

×

21

Publications

757

Citations

15

H-Index

YearCitations

Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site

Hidetoshi Hayashi, Yuichi Takiguchi, Hironobu Minami,

JAMA Oncology

2020

114

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma,

JAMA Oncology

2022

85

Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study

Chihiro Kondoh, Kohei Shitara, Motoo Nomura,

BMC Palliative Care

2015

81

A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol

Satoru Miura, Tateaki Naito, Shuichi Mitsunaga,

BMC Cancer

2019

55

Prognostic Impact of the 6th and 7th American Joint Committee on Cancer TNM Staging Systems on Esophageal Cancer Patients Treated With Chemoradiotherapy

Motoo Nomura, Kohei Shitara, Takeshi Kodaira,

International Journal of Radiation Oncology*Biology*Physics

2011

51

Muscle wasting associated with the long-term use of mTOR inhibitors

Bishal Gyawali, Tomoya Shimokata, Kazunori Honda,

Molecular and Clinical Oncology

2016

51

Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma

Shigenori Kadowaki, Yasushi Yatabe, Hitoshi Hirakawa,

Case Reports in Oncology

2013

46

Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial

Brian I. Rini, Michael B. Atkins, Elizabeth R. Plimack,

European Urology Oncology

2021

31

A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure–Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial)

Takeshi Suzuki, Yasutaka Sukawa, Chiyo K. Imamura,

Clinical Colorectal Cancer

2019

29

Cabozantinib in advanced renal cell carcinoma: A phase II, open‐label, single‐arm study of Japanese patients

Yoshihiko Tomita, Katsunori Tatsugami, Noboru Nakaigawa,

International Journal of Urology

2020

27

Page 1